Mupadolimab vs Uliledlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: CD73 · full Non-Small Cell Lung Cancer pipeline

Mupadolimab

Developed by Corvus Pharmaceuticals and partners

Phase 1 in Non-Small Cell Lung Cancermonoclonal antibody
Weak signal

NCT03454451 · Phase 1 · completed

Although the registry labels the allocation as randomized, none of the six groups received a placebo or an inactive comparator, and there was no blinding, so this functions as an open-label dose-escalation and combination study rather than a controlled comparison. The main goals were safety, tolerated dose, and drug levels. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab. (From start of treatment to end of treatment, up to 36 months); Incidence of treatment-emergent adverse events as assessed by NCI CTCAE v.4.03, of CPI-006 as single agent and in combination with ciforadenant and with pembrolizumab. (From start of treatment to end of treatment, up to 36 months); Identify the MDL(maximum dose level) of single agent CPI-006 (From start of treatment to end of treatment, up to 36 months): Mupadolimab (CPI-006) monotherapy/combination in advanced cancers: doses up to 18 mg/kg tolerated without DLTs; minor tumor regression (below PR threshold) in 5 patients with prior PD.

Result source: NCT03454451

Uliledlimab

Developed by TJ Biopharma Co., Ltd. and partners

Phase 2/3 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT06984588 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMupadolimabUliledlimab
PFS, median—Not reported—Trial running · NCT06984588
OS, median—Not reported—Trial running · NCT06984588
ORR—Not reported—Trial running · NCT06984588
Duration of response, median—Not reported—Trial running · NCT06984588

PFS, median

Mupadolimab
—Not reported
Uliledlimab
—Trial running · NCT06984588

OS, median

Mupadolimab
—Not reported
Uliledlimab
—Trial running · NCT06984588

ORR

Mupadolimab
—Not reported
Uliledlimab
—Trial running · NCT06984588

Duration of response, median

Mupadolimab
—Not reported
Uliledlimab
—Trial running · NCT06984588
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Uliledlimab: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Mupadolimab
Mupadolimab (CPI-006) monotherapy/combination in advanced cancers: doses up to 18 mg/kg tolerated without DLTs; minor tumor regression (below PR threshold) in 5 patients with prior PD. NCT03454451 · Phase 1 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mupadolimab's landscape · Uliledlimab's landscape